Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"LANK-2": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia

NCT02074657 is registered in ClinicalTrials.gov with Hospital Universitario La Paz as lead sponsor.

NCT NCT02074657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02074657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"LANK-2": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia
Lead sponsor
Hospital Universitario La Paz
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2014
Completion date
September 30, 2016
Enrollment
13 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory paediatric acute leukaemia